Professor David Hume AO FMedSci FRSE graduated with First Class Honours and a PhD in biochemistry from the Australian National University. He did his postdoctoral research in the Sir William Dunn School of Pathology in Oxford with Siamon Gordon, where he established his career focus on the biology of macrophages. This research was recognised with the Bonazinga Award for Excellence from the Society for Leukocyte Biology in 2011. He was subsequently a Research Fellow at the John Curtin School of Medical Research in Canberra and MD Anderson Cancer Center in Houston before joining the nascent Centre for Molecular Biology and Biotechnology at the University of Queensland in 1988. This Centre grew over the next 20 years to become the Institute for Molecular Bioscience (IMB). At the IMB he was Director of the ARC Centre for Functional and Applied Genomics and Deputy Director of the CRC for Chronic Inflammatory Diseases. He has published extensively on transcription regulation and transcriptomics and from 2000 to 2015 he was a senior member of the FANTOM Consortium, led by RIKEN in Japan. In 2006, he was appointed Director of The Roslin Institute at the University of Edinburgh and expanded his interests in both macrophage biology and transcriptomics to multiple species other than humans and experimental animals. He returned to Australia in 2018 and is currently a Professorial Fellow at Mater Research Institute-University of Queensland where he shares a research group with Dr Kate Irvine. He currently holds an NHMRC-funded Investigator Grant and grant funding from the Australian Research Council. His major focus is on the regulation and function of the macrophage colony-stimulating factor receptor (CSF1R) and potential utility of the major ligand (CSF1) in tissue repair and regenerative medicine.
Current and recent research funding
2018-2020 Osteal macrophages as therapeutic targets for fracture repair. A.Pettit, DA Hume, M Wullschleger, L Raggatt, J. Prins. NHMRC $638,000
2019-2021 CSF1R and the control of microglial function. DA Hume, KM Summers NHMRC $467,127
2019-2021 CSF1 therapy for chronic liver disease. KM Irvine, DA Hume, J. Fawcett, A.Clouston NHMRC $497,127
2021-2023 Macrophage control of mammalian growth and development Australian Research Council Discovery Grant. DA Hume, KM Irvine, C. Pridans $564,600
2022-2026 Macrophage Biology in Health and Disease. NHMRC Leadership L3 Investigator Grant. $3,474,000
In: Journal of Cellular Physiology, vol. 96, no. 3, pp. 303–308, 1978, ISSN: 00219541.
In: Hormone and Metabolic Research, vol. 10, no. 5, pp. 449–450, 1978, ISSN: 00185043.
In: Biochemical Journal, vol. 174, no. 3, pp. 711–716, 1978, ISSN: 02646021.
Aerobic glycolysis and lymphocyte transformation (Journal Article)
In: Biochemical Journal, vol. 174, no. 3, pp. 703–709, 1978, ISSN: 02646021.
In: BBA – General Subjects, vol. 500, no. 1, pp. 89–102, 1977, ISSN: 03044165.
In: Biochemical Education, vol. 4, no. 1, pp. 13–14, 1976, ISSN: 03074412.